Repository logo

Molecular Criteria for Defining the Naive Human Pluripotent State.

Published version

Change log


Theunissen, Thorold W 
Friedli, Marc 
He, Yupeng 
Planet, Evarist 
O'Neil, Ryan C 


Recent studies have aimed to convert cultured human pluripotent cells to a naive state, but it remains unclear to what extent the resulting cells recapitulate in vivo naive pluripotency. Here we propose a set of molecular criteria for evaluating the naive human pluripotent state by comparing it to the human embryo. We show that transcription of transposable elements provides a sensitive measure of the concordance between pluripotent stem cells and early human development. We also show that induction of the naive state is accompanied by genome-wide DNA hypomethylation, which is reversible except at imprinted genes, and that the X chromosome status resembles that of the human preimplantation embryo. However, we did not see efficient incorporation of naive human cells into mouse embryos. Overall, the different naive conditions we tested showed varied relationships to human embryonic states based on molecular criteria, providing a backdrop for future analysis of naive human pluripotency.



DNA methylation, X chromosome reactivation, embryonic stem cells, imprinting, mouse-human chimeras, pluripotency, transposable elements, Animals, Blastocyst, Cell Differentiation, Cell Line, Chimera, Chromosomes, Human, X, Cleavage Stage, Ovum, DNA Methylation, DNA Transposable Elements, DNA, Mitochondrial, Female, Gene Expression Profiling, Genome, Human, Genomic Imprinting, Human Embryonic Stem Cells, Humans, Male, Mice, Mitochondria, Morula, Pluripotent Stem Cells, Polymerase Chain Reaction, Transcription, Genetic

Journal Title

Cell Stem Cell

Conference Name

Journal ISSN


Volume Title



Elsevier BV
Wellcome Trust (098889/Z/12/Z)
This study was supported by grants from the Simons Foundation (SFLIFE #286977 to R.J) and in part by the NIH (RO1-CA084198) to R.J., from the Swiss National Science Foundation and the European Research Council (KRABnKAP, No. 268721) to D.T. The work in J.R.E’s laboratory was supported by the Howard Hughes Medical Institute and Gordon and Betty Moore Foundation (GBMF3034) and the Mary K. Chapman Foundation. J.R.E is an Investigator of the Howard Hughes Medical Institute. T.W.T. is supported by a Sir Henry Wellcome Postdoctoral Fellowship (098889/Z/12/Z), J.P. by a Foundation Bettencourt Award and by the Association pour la Recherche sur le Cancer (ARC), M.I. by a postdoctoral training grant from the Fonds de la Recherche en Santé du Québec. R.J. is co-founder of Fate Therapeutics and an adviser to Stemgent.